Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.57 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.57 |
| ▸ | HDAC11 known ✓ | Q96DB2 | 5/20 | 0.55 |
| ▸ | GABRP known ✓ | O00591 | 1/20 | 0.55 |
| ▸ | GABRD known ✓ | O14764 | 1/20 | 0.55 |
| ▸ | HDAC3 known ✓ | O15379 | 1/20 | 0.55 |
| ▸ | GABRA1 known ✓ | P14867 | 1/20 | 0.55 |
| ▸ | GABRB1 known ✓ | P18505 | 1/20 | 0.55 |
| ▸ | GABRG2 known ✓ | P18507 | 1/20 | 0.55 |
| ▸ | GABRB3 known ✓ | P28472 | 1/20 | 0.55 |
| ▸ | SLC6A1 known ✓ | P30531 | 1/20 | 0.55 |
| ▸ | GABRA5 known ✓ | P31644 | 1/20 | 0.55 |
| ▸ | GABRA3 known ✓ | P34903 | 1/20 | 0.55 |
| ▸ | GABRA2 known ✓ | P47869 | 1/20 | 0.55 |
| ▸ | GABRB2 known ✓ | P47870 | 1/20 | 0.55 |
| ▸ | GABRA4 known ✓ | P48169 | 1/20 | 0.55 |
| ▸ | HDAC4 known ✓ | P56524 | 1/20 | 0.55 |
| ▸ | GABRE known ✓ | P78334 | 1/20 | 0.55 |
| ▸ | HDAC1 known ✓ | Q13547 | 1/20 | 0.55 |
| ▸ | GABRA6 known ✓ | Q16445 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3143617 | 1.00 | LMNA (0.69) | LMNABLMNPSR1TSHRNFKB1 | |
| Hydrochloric Acid SCHEMBL2220731 | 0.97 | TSHR (0.71) | LMNABLMNPSR1TSHRNFKB1 | |
| Hydrochloric Acid SCHEMBL1802789 | 0.97 | TSHR (0.71) | LMNABLMNPSR1TSHRNFKB1 | |
| Hydrochloric Acid SCHEMBL1471000 | 0.97 | TSHR (0.71) | LMNABLMNPSR1TSHRNFKB1 | |
| SCHEMBL227399 | 0.97 | LMNA (0.73) | LMNABLMNPSR1TSHRNFKB1 | |
| Adipic Acid SCHEMBL27494750 | 0.97 | LMNA (0.73) | LMNABLMNPSR1TSHRNFKB1 | |
| Adipic Acid SCHEMBL27793455 | 0.97 | LMNA (0.73) | LMNABLMNPSR1TSHRNFKB1 | |
| SCHEMBL25255715 | 0.94 | TSHR (0.75) | LMNABLMNPSR1TSHRNFKB1 | |
| SCHEMBL19599369 | 0.94 | TSHR (0.75) | LMNABLMNPSR1TSHRNFKB1 | |
| SCHEMBL20651676 | 0.94 | TSHR (0.75) | LMNABLMNPSR1TSHRNFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4400121-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING AND/OR PREVENTING CANCER | Toray Industries, Inc. (JP) | 2024-07-17 | — | — | EP | disclosed |
| US-20240180150-A1 | Green Closed Loop Bio-waste Refining Process For Producing Smart Active Extracts and Delivery Systems for Their Application | CELLACURE LLC (US) | 2024-06-06 | — | — | US | disclosed |
| EP-3515476-B1 | FUSION COMPRISING A CELL PENETRATING PEPTIDE, A MULTIEPITOPE AND A TLR PEPTIDE AGONIST FOR TREATMENT OF CANCER | AMAL THERAPEUTICS SA (CH) | 2024-05-22 | — | — | EP | disclosed |
| EP-3693009-B1 | A NOVEL COMPLEX COMPRISING A CELL PENETRATING PEPTIDE, A CARGO AND A TLR PEPTIDE AGONIST FOR TREATMENT OF COLORECTAL CANCER | AMAL THERAPEUTICS SA (CH) | 2024-02-21 | — | — | EP | disclosed |
| EP-3429618-B1 | COMBINATION OF AN IMMUNE CHECKPOINT MODULATOR AND A COMPLEX COMPRISING A CELL PENETRATING PEPTIDE, A CARGO AND A TLR PEPTIDE AGONIST FOR USE IN MEDICINE | AMAL THERAPEUTICS SA (CH) | 2024-02-21 | — | — | EP | disclosed |
| US-20220213546-A1 | PROTOCOL FOR DETECTING INTERACTIONS WITHIN ONE OR MORE DNA MOLECULES WITHIN A CELL | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2022-07-07 | — | — | US | disclosed |
| US-11338027-B2 | Fusion comprising a cell penetrating peptide, a multi epitope and a TLR peptide agonist for treatment of cancer | AMAL THERAPEUTICS SA (CH) | 2022-05-24 | — | — | US | disclosed |
| US-20220096643-A1 | Acryloyloxyethylphosphorylcholine Containing Polymer Conjugates And Their Preparation | KODIAK SCIENCES INC (US) | 2022-03-31 | — | — | US | disclosed |
| US-20210085768-A1 | Fusion Comprising A Cell Penetrating Peptide, A Multi Epitope And A TLR Peptide Agonist For Treatment Of Cancer | AMAL THERAPEUTICS SA (CH) | 2021-03-25 | — | — | US | disclosed |
| CN-109942771-B | Method for forming shoe sole | 温州市显兴鞋材有限公司 | 2021-02-26 | — | — | CN | disclosed |
| US-20100297180-A1 | BOTULINUM NEUROTOXIN VACCINE | THE SECRETARY OF STATE FOR HEALTH (GB) | 2010-11-25 | — | — | US | disclosed |
| EP-2208737-A1 | Complement factor H-derived short consensus repeat-antibody constructs | Medizinische Universität Innsbruck (AT) | 2010-07-21 | — | — | EP | disclosed |
| US-20100166700-A1 | Acryloyloxyethylphosphorylcholine Containing Polymer Conjugates and Their Preparation | OLIGASIS CORPORATION (US) | 2010-07-01 | — | — | US | disclosed |
| US-20090252731-A1 | Multivalent Carriers of Bi-Specific Antibodies | IMMUNOMEDICS, INC. (US) | 2009-10-08 | — | — | US | disclosed |
| WO-2009056955-A1 | AMINE-BEARING PHOSPHOLIPIDS (ABPS), THEIR SYNTHESIS AND USE | UNIVERSITY OF BASEL (CH) | 2009-05-07 | — | — | WO | disclosed |
| US-20040241748-A1 | Self-assembling arrays and uses thereof | POINTILLISTE, INC. | 2004-12-02 | — | — | US | disclosed |
| US-20040023248-A1 | Using dendrimeric biopolymers to identify nucleotide sequences; microarrays | WHITEHEAD INSTITIUTE FOR BIOMEDICAL RESEARCH | 2004-02-05 | — | — | US | disclosed |
| EP-0248621-B1 | REAGENT FOR IMMUNOASSAY | KABUSHIKI KAISHA TOSHIBA (JP) | 1992-08-26 | — | — | EP | disclosed |
| EP-0248621-A2 | Reagent for immunoassay | KABUSHIKI KAISHA TOSHIBA (JP) | 1987-12-09 | — | — | EP | disclosed |
| US-4245005-A | CHROMATOGRAPHY, CROSSLINKED COATING | PURDUE RESEARCH FOUNDATION (US) | 1981-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100166700-A1 | Acryloyloxyethylphosphorylcholine Containing Polymer Conjugates and Their Preparation | PHOSPHO1, PCTP, SGMS1 | SLC6A2 2941/4885SLC6A3 3236/4885HDAC11 962/4885 |
| US-20220096643-A1 | Acryloyloxyethylphosphorylcholine Containing Polymer Conjugates And Their Preparation | PHOSPHO1, PCTP, SGMS1 | SLC6A2 2941/4885SLC6A3 3236/4885HDAC11 962/4885 |
| US-20090252731-A1 | Multivalent Carriers of Bi-Specific Antibodies | FCGR3B, FCGR2A, FCGR1A | SLC6A2 1294/4885SLC6A3 1903/4885HDAC11 4494/4885 |
| US-20100297180-A1 | BOTULINUM NEUROTOXIN VACCINE | BTN3A1, GZMB, NGLY1 | SLC6A2 3373/4885SLC6A3 4630/4885HDAC11 4864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.